Vitamin A analogue protects against breast cancerBMJ 1999; 319 doi: https://doi.org/10.1136/bmj.319.7220.1312c (Published 13 November 1999) Cite this as: BMJ 1999;319:1312
- Janice Hopkins Tanne
- New York
A synthetic vitamin A analogue, fenretinide, reduced the rate of second breast cancers in premenopausal women in a study by Dr Umberto Veronesi of the Istituto Nazionale Tumori and the European Institute of Oncology in Milan and colleagues (Journal of the National Cancer Institute 1999;91:1847-56).
In postmenopausal women, however, it seemed to increase the risk of a second breast cancer. The drug also reduced the rate of ovarian cancer in women under 50.
“Chemoprevention is relatively new. The carcinogenic process is multi-step and this substance might interfere with and stop the process,” said Dr Veronesi at a press conference …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial